Phase 2 Kidney Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who are scheduled to have a procedure called ureteroscopic laser ablation to treat a tumour in the renal pelvis (the part of the kidney where urine collects)
• People whose tumour is in the renal pelvis, has been confirmed as a type of cancer called upper tract urothelial carcinoma through biopsy, urine testing, or imaging scans (such as CT, MRI, or PET-CT), has not spread to lymph nodes or other parts of the body, is at an early-to-intermediate stage (T1–T2N0M0), and measures less than 3 cm across at its widest point
• People with an expected survival of more than 12 weeks
• People with a general health and activity level rated 0–2 on a standard medical scale, meaning they are able to carry out at least some daily activities (confirm with trial site)
• People who agree to provide blood, urine, and tissue samples for laboratory testing during the trial
• People whose blood counts, liver function, and kidney function meet specific minimum levels as measured by laboratory tests (confirm with trial site for exact values)
• People who are willing to take part and able to follow the study requirements

Who may not be able to join:

• People who currently have an active cancer in another part of the body (people with a past cancer that has been treated and is now stable may still be considered)
• People who have this same type of cancer in both kidneys
• People who have urothelial cancer in the ureter or bladder, unless the bladder cancer is a non-muscle-invasive type that can be fully removed with a standard bladder procedure
• People who have received a live attenuated (weakened) vaccine within 4 weeks before starting treatment, or who plan to receive one during the study
• People with an active or known autoimmune disease, or a suspected history of one
• People with a known history of a primary immune system deficiency
• People who have previously received an organ transplant or a stem cell transplant from another person
• People who are pregnant or breastfeeding
• People with untreated active Hepatitis B or Hepatitis C infection (people already receiving antiviral treatment with monitored viral levels may be considered at the treating doctor's discretion)
• People who have taken immune-suppressing medications within 4 weeks before starting treatment, with the exception of certain low-dose or topical steroids (confirm with trial site)
• People with a known or suspected allergy to the study drugs Tislelizumab or Nab-Paclitaxel
• People with active tuberculosis
• People who have previously been treated with certain types of immunotherapy drugs (PD-1, PD-L1, or CTLA-4 inhibitors)
• People who are currently taking part in another clinical trial
• People of reproductive age who are not using effective contraception
• People with certain serious uncontrolled health conditions, including HIV infection, severe uncontrolled infections, uncontrolled psychiatric or neurological conditions (such as epilepsy or dementia), unstable heart, lung, liver, or kidney disease, uncontrolled high blood pressure, active bleeding or new blood clots, or kidney failure requiring dialysis

Important: Always verify eligibility with the trial site directly before applying.